Pulmonary Pleomorphic Carcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Pulmonary Pleomorphic Carcinoma trials may be worth asking about

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06789172

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this s…

United States, Australia, United Kingdom146 participantsStarted 2025-01-23Updated 2026-06-11

Treatment: OKN4395, Pembrolizumab

All recent trials (4 shown)

TerminatedPhase 1

NCT05827614

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With…

BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy…

United States85 participantsStarted 2023-03-24Updated 2026-06-08

Treatment: BBI-355, Erlotinib

CompletedPhase 2

NCT05375734

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pul…

Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .

China29 participantsStarted 2021-08-17Updated 2026-05-28

Pulmonary Pleomorphic Carcinoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

All recent trials (4 shown)

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With…

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pul…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

All recent trials (4 shown)

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With…

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pul…

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)